IDEXX Laboratories reported second-quarter 2026 revenue growth of approximately 10% as reported and 9% organically, driven by a 10.3% organic increase in CAG Diagnostics recurring revenue with double-digit gains in both the US and international regions. The company placed over 5,200 premium instruments, including approximately 1,600 IDEXX inVue Dx analyzers, while US same-store clinical visits declined an estimated 1.3%. Gross margin reached 64%, up roughly 120 basis points on a comparable basis, and reported operating margin hit 35% with comparable operating margin gains of 110 basis points. Earnings per share were $4.27, up 18% as reported and 15% on a comparable basis, and free cash flow was $323 million in the quarter and $557 million for the first half of 2026. IDEXX updated its full-year 2026 revenue outlook to a range of $4.7 billion to $4.745 billion and raised its EPS guidance to $14.69 to $14.94 per share.
IDEXX Laboratories IncQ2 revenue up 10%, EPS up 18%, raised full-year guidance
